browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
7395a9aa-1397-4a8b-974b-c625b5df2d83
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 16:55:38
Income (reported)
—
Expenses (reported)
$390,000
Expenses method
A
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

PTC THERAPEUTICS, INC.

Biopharmaceutical therapies for rare pediatric diseases

Contact
JONATHAN MCPHERSON
Phone
+1 202-887-1400
Address
zip:07080, city:South Plainfield, state:NJ, street:100 Corporate Court
Client

PTC THERAPEUTICS, INC.

State
NJ
Country
US
Government-entity client
false
Effective date
2020-08-24
Issues lobbied + lobbyists (5)

HCR — Health Issues

Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 1262 - Give Kids a Chance Act of 2025 and S. 932 - Give Kids a Chance Act Issues related to Public Law No. 119-21 - The One Big Beautiful Bill Act of 2025

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

MED — Medical/Disease Research/Clinical Labs

Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria Awareness of Duchenne Muscular Dystrophy

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

MMM — Medicare/Medicaid

Innovative payment methodologies for cell and gene therapies Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to the Medicaid Drug Rebate Program Issues related to implementation of Public Law No. 117-169 - The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 946 - The Optimizing Research Progress Hope and New Cures Act and the small molecule penalty, including H.R. 1492 - The Ensuring Pathways to Innovative Cures Act

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TAX — Taxation/Internal Revenue Code

Issues related to Section 174 R&D Amortization, including H.R. 1990 - American Innovation and R&D Competitiveness Act of 2025 Issues related to the Orphan Drug Tax Credit, including H.R. 1414 - Camerons Law Issues related to international reference pricing

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TRD — Trade (domestic/foreign)

Issues related to tariffs

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.